Melancholic symptoms during concurrent olanzapine and fluoxetine

Annals of Clinical Psychiatry

Volumn 12, Issue 3, 2000, Pages 167-170

  Nelson, Leigh Anne ^a   Swartz, Conrad M ^b  

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b SOUTHERN ILLINOIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Drug interaction; Fluoxetine; Melancholia; Olanzapine; Toxicity

Indexed keywords

BUSPIRONE; FLUOXETINE; LEVOTHYROXINE; MIRTAZAPINE; OLANZAPINE; PAROXETINE; SERTRALINE; TRAZODONE; VENLAFAXINE; ZOLPIDEM;

ADULT; ARTICLE; CASE REPORT; DEPRESSION; DRUG SAFETY; ELECTROCONVULSIVE THERAPY; FEMALE; HUMAN; MELANCHOLIA; PRIORITY JOURNAL; SUICIDAL BEHAVIOR; SYMPTOMATOLOGY; TREATMENT OUTCOME;

ADULT; ANTIDEPRESSIVE AGENTS; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; BENZODIAZEPINES; DEPRESSIVE DISORDER; DRUG THERAPY, COMBINATION; FEMALE; FLUOXETINE; HUMANS; PIRENZEPINE;

EID: 0033857929     PISSN: 10401237     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1009021119654     Document Type: Article

References (25)

1. Olanzapine augmentation of fluoxetine in the treatment of refractory obsessive-compulsive disorder
2. Olanzapine augmentation of fluoxetine in the treatment of trichotillomania
3. Adjunctive use of olanzapine in mood disorders: Five case reports
4. Serum concentrations of clozapine and its major metabolites: Effects of cotreatment with fluoxetine or valproate
5. Serum levels of clozapine and norclozapine in patients treated with selective serotonin reuptake inhibitors
6. An updated review of the metabolism of clozapine and olanzapine
7. Identification of the human cytochromes P450 responsible for the in vitro formation of the major oxidative metabolites of the antipsychotic agent olanzapine
8. Cytochrome P450 enzymes: Interpretation of their interactions with selective serotonin reuptake inhibitors. Part II
9. Olanzapine serum concentrations in psychiatric patients given standard doses: The influence of comedication
10. Fluovoxamine is a potent inhibitor of cytochrome P4501A2
11. In vitro interaction of the antipsychotic agent olanzapine with human cytochromes P450 CYP2C9, CYP2C19, CYP2D6 and CYP3A
12. Increases in plasma concentration of m-chlorophenylpiperazine, but not trazodone, with low-dose haloperidol
13. Effects of carbamazepine coadministration on plasma concentrations of trazodone and its active metabolite, m-chlororphenylpiperazine
14. Trazodone is metabolized to m-chlorophenylpiperazine by CYP3A4 from human sources
15. Adverse interactions encountered when using trazodone to treat insomnia associated with fluoxetine
16. Possible trazodone potentiation of fluoxetine: A case series
17. Metabolism of anxiolytics and hypnotics: Benzodiazepines, buspirone, zoplicone, and zolpidem
18. Metabolism and disposition of buspirone
19. Metabolism of the antianxiety drug buspirone in human subjects
20. Plasma buspirone concentrations are greatly increased by erythromycin and itraconazole
21. The effect of co-administration of zolpidem with fluoxetine: Pharmacokinetics and pharmacodynamics
22. Metabolism of the newer antidepressants: An overview of the pharmacological and pharmacokinetic implications
23. Serotonin syndrome with mirtazapine-fluoxetine combination